TCG Advisory Services LLC Increases Stake in Novo Nordisk A/S (NYSE:NVO)

TCG Advisory Services LLC grew its position in Novo Nordisk A/S (NYSE:NVO) by 64.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 5,635 shares of the company’s stock after buying an additional 2,218 shares during the period. TCG Advisory Services LLC’s holdings in Novo Nordisk A/S were worth $583,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Xponance Inc. bought a new stake in shares of Novo Nordisk A/S in the third quarter worth approximately $248,000. Stratos Wealth Partners LTD. raised its stake in Novo Nordisk A/S by 228.9% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 17,857 shares of the company’s stock valued at $1,624,000 after buying an additional 12,427 shares during the last quarter. Stratos Wealth Advisors LLC bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at $237,000. Bank of New York Mellon Corp lifted its holdings in shares of Novo Nordisk A/S by 97.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 863,598 shares of the company’s stock valued at $78,536,000 after buying an additional 425,392 shares during the period. Finally, Bailard Inc. boosted its stake in shares of Novo Nordisk A/S by 104.7% in the 3rd quarter. Bailard Inc. now owns 8,191 shares of the company’s stock worth $745,000 after buying an additional 4,189 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO traded down $0.97 during midday trading on Friday, reaching $123.05. The stock had a trading volume of 5,932,926 shares, compared to its average volume of 3,905,318. The company has a market capitalization of $552.19 billion, a price-to-earnings ratio of 42.43, a price-to-earnings-growth ratio of 2.06 and a beta of 0.43. Novo Nordisk A/S has a 12-month low of $75.56 and a 12-month high of $138.28. The stock has a 50-day moving average of $127.20 and a 200-day moving average of $113.10. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 92.21% and a net margin of 36.56%. The business had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. As a group, research analysts anticipate that Novo Nordisk A/S will post 3.32 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on NVO. Morgan Stanley started coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, April 18th. BMO Capital Markets initiated coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target on the stock. Finally, UBS Group started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating for the company. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.